Page last updated: 2024-12-09

tocopherylquinone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

tocopherylquinone: RN refers to (3R-(3R*,7R*,11R*))-isomer; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID2734086
CHEMBL ID1223852
SCHEMBL ID3045963
MeSH IDM0043000

Synonyms (48)

Synonym
alpha-tocopherylquinone
bdbm50041386
chembl1223852 ,
d-alpha-tocopherylquinone
7559-04-8
.alpha.-tocopherylquinone
einecs 231-450-8
p-benzoquinone, 2-(3-hydroxy-3,7,11,15-tetramethylhexadecyl)-3,5,6-trimethyl-
2-(3-hydroxy-3,7,11,15-tetramethylhexadecyl)-3,5,6-trimethyl-p-benzoquinone
alpha-tocoquinone
2,5-cyclohexadiene-1,4-dione, 2-(3-hydroxy-3,7,11,15-tetramethylhexadecyl)-3,5,6-trimethyl-, (3r-(3r*,7r*,11r*))-
tocopherylquinone
alpha-tocopheroquinone
ai3-51910
alpha-tocopherolquinone
metarene
alpha-tocopherol quinone
vitamin e quinone
atq ,
T2283
A0001 ,
vitamin e quinone (d-form)
2-[(3r,7r,11r)-3-hydroxy-3,7,11,15-tetramethylhexadecyl]-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione
zo763k43xr ,
unii-zo763k43xr
2,5-cyclohexadiene-1,4-dione, 2-((3r,7r,11r)-3-hydroxy-3,7,11,15-tetramethylhexadecyl)-3,5,6-trimethyl-
tocoquinone
a-0001 ,
tocoquinone [inci]
tocopherylquinone [who-dd]
alpha-tocopherylquinone s
d-.alpha.-tocopherol quinone
epia-0001
CCG-207902
2-[(3r,7r,11r)-3-hydroxy-3,7,11,15-tetramethyl-hexadecyl]-3,5,6-trimethyl-1,4-benzoquinone
SCHEMBL3045963
mfcd00135657
d-alpha-tocopherylquinone, aldrichcpr
AKOS032962204
DTXSID501009892
DB14094
2-((3r,7r,11r)-3-hydroxy-3,7,11,15-tetramethylhexadecyl)-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione
Q27295808
T72911
d-| inverted exclamation mark-tocopherylquinone
F82125
78419-32-6
metarene; -tocopherylquinone

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Dose escalation was based on safety assessment, and proceeding dose levels were selected based on interim pharmacokinetic analyses."( Use of an adaptive study design in single ascending-dose pharmacokinetics of A0001 (α-tocopherylquinone) in healthy male subjects.
Hawi, A; Heald, S; Sciascia, T, 2012
)
0.6

Bioavailability

ExcerptReferenceRelevance
" Since the responsible bacterial reactions may be dependent on vitamin K as an electron acceptor it is suggested that poorly absorbed vitamin K antagonists, specifically alpha-tocopherylquinone, may be capable of inhibiting these reactions and may therefore prove effective in treating ulcerative colitis and in preventing the development of colon cancer."( Ulcerative colitis: the result of an altered bacterial metabolism of bile acids or cholesterol.
Bennet, JD, 1986
)
0.46
" Recent investigations into vitamin E metabolism have also highlighted important new areas of research, such as the potential for high dose vitamin E supplementation to interfere with drug metabolism, as well as alternative methods to alter vitamin E bioavailability in vivo."( Vitamin E metabolism.
Croft, KD; Wu, JH,
)
0.13

Dosage Studied

ExcerptRelevanceReference
" Exposure was highly dependent on food and dosing frequency."( Use of an adaptive study design in single ascending-dose pharmacokinetics of A0001 (α-tocopherylquinone) in healthy male subjects.
Hawi, A; Heald, S; Sciascia, T, 2012
)
0.6
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Tyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)IC50 (µMol)35.09000.70004.58049.4500AID1176098
Tyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)IC50 (µMol)3.85000.00053.49849.7600AID1176097
M-phase inducer phosphatase 2Homo sapiens (human)IC50 (µMol)23.23000.10002.31039.5100AID1176099
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (65)

Processvia Protein(s)Taxonomy
negative regulation of transcription by RNA polymerase IITyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of cell population proliferationTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of tumor necrosis factor-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of lipid storageTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
B cell differentiationTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
T cell differentiationTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
erythrocyte differentiationTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
peptidyl-tyrosine dephosphorylationTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
insulin receptor recyclingTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of epidermal growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of tyrosine phosphorylation of STAT proteinTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
glucose homeostasisTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of macrophage differentiationTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
positive regulation of gluconeogenesisTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of inflammatory responseTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of T cell receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of chemotaxisTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
regulation of type II interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of type II interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of type I interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of interleukin-6-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
regulation of hepatocyte growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of interleukin-2-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of interleukin-4-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of macrophage colony-stimulating factor signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of positive thymic T cell selectionTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
positive regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
positive regulation of PERK-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of platelet-derived growth factor receptor-beta signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of receptor signaling pathway via JAK-STATTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
positive regulation of JUN kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
actin cytoskeleton organizationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of endocytosisTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of vascular endothelial growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulum unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of intracellular protein transportTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cellular response to unfolded proteinTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
platelet-derived growth factor receptor-beta signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor recyclingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of MAP kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of type I interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of protein tyrosine kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of hepatocyte growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of PERK-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of receptor catabolic processTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
G2/M transition of mitotic cell cycleM-phase inducer phosphatase 2Homo sapiens (human)
mitotic cell cycleM-phase inducer phosphatase 2Homo sapiens (human)
oocyte maturationM-phase inducer phosphatase 2Homo sapiens (human)
protein phosphorylationM-phase inducer phosphatase 2Homo sapiens (human)
female meiosis IM-phase inducer phosphatase 2Homo sapiens (human)
positive regulation of cell population proliferationM-phase inducer phosphatase 2Homo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycleM-phase inducer phosphatase 2Homo sapiens (human)
positive regulation of cytokinesisM-phase inducer phosphatase 2Homo sapiens (human)
positive regulation of mitotic cell cycleM-phase inducer phosphatase 2Homo sapiens (human)
cell divisionM-phase inducer phosphatase 2Homo sapiens (human)
positive regulation of G2/MI transition of meiotic cell cycleM-phase inducer phosphatase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (16)

Processvia Protein(s)Taxonomy
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
integrin bindingTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
protein kinase bindingTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
syntaxin bindingTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
receptor tyrosine kinase bindingTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
STAT family protein bindingTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
RNA bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
zinc ion bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
enzyme bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
receptor tyrosine kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cadherin bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
ephrin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein phosphatase 2A bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
phosphoprotein phosphatase activityM-phase inducer phosphatase 2Homo sapiens (human)
protein tyrosine phosphatase activityM-phase inducer phosphatase 2Homo sapiens (human)
protein bindingM-phase inducer phosphatase 2Homo sapiens (human)
protein kinase bindingM-phase inducer phosphatase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (16)

Processvia Protein(s)Taxonomy
plasma membraneTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
nucleoplasmTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartmentTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
endosome lumenTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
nucleusTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
plasma membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial matrixTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial cristaTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endosome lumenTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
sorting endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmic side of endoplasmic reticulum membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein-containing complexTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
spindle poleM-phase inducer phosphatase 2Homo sapiens (human)
nucleoplasmM-phase inducer phosphatase 2Homo sapiens (human)
centrosomeM-phase inducer phosphatase 2Homo sapiens (human)
cytosolM-phase inducer phosphatase 2Homo sapiens (human)
nucleusM-phase inducer phosphatase 2Homo sapiens (human)
cytoplasmM-phase inducer phosphatase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (55)

Assay IDTitleYearJournalArticle
AID641757Prolongation of partial thromboplastin time in male Wistar rat2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Towards a modern definition of vitamin E-evidence for a quinone hypothesis.
AID641745Volume of distribution in mouse plasma at 5 mg/kg, iv by HPLC analysis2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Towards a modern definition of vitamin E-evidence for a quinone hypothesis.
AID641748Inhibition of CYP3A3 at 10 uM2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Towards a modern definition of vitamin E-evidence for a quinone hypothesis.
AID641735AUC (0 to infinity) in mouse plasma at 5 mg/kg, iv by HPLC analysis2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Towards a modern definition of vitamin E-evidence for a quinone hypothesis.
AID642438AUCt in rat plasma at 100 mg/kg, po by HPLC analysis2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Towards a modern definition of vitamin E-evidence for a quinone hypothesis.
AID1176105Inhibition of SHP1 (unknown origin) using pNPP as substrate at 20 ug/ml by spectrophotometry2015Bioorganic & medicinal chemistry, Jan-01, Volume: 23, Issue:1
Bioactive constituents from the green alga Caulerpa racemosa.
AID641754Toxicity in Wistar rat assessed as changes in body weight up to 2000 mg/kg, qd for 14 days2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Towards a modern definition of vitamin E-evidence for a quinone hypothesis.
AID1233173Antimicrobial activity against Escherichia coli after 5 to 12 hrs by micro broth dilution assay2015Bioorganic & medicinal chemistry letters, Jul-01, Volume: 25, Issue:13
Synthesis and bioactivity of tripolinolate A from Tripolium vulgare and its analogs.
AID641743Oral bioavailability in mouse plasma at 10 mg/kg by HPLC analysis2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Towards a modern definition of vitamin E-evidence for a quinone hypothesis.
AID641750Inhibition of CYP2C19 at 10 uM2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Towards a modern definition of vitamin E-evidence for a quinone hypothesis.
AID642429Therapeutic index, ratio of LC50 to GI50 for human FRDA primary patient fibroblasts2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Towards a modern definition of vitamin E-evidence for a quinone hypothesis.
AID642427Growth inhibition of human FRDA primary patient fibroblasts after 48 hrs by calcein-AM-based cell viability assay2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Towards a modern definition of vitamin E-evidence for a quinone hypothesis.
AID1176098Inhibition of TC-PTP (unknown origin) using pNPP as substrate by spectrophotometry2015Bioorganic & medicinal chemistry, Jan-01, Volume: 23, Issue:1
Bioactive constituents from the green alga Caulerpa racemosa.
AID641742Half life in dog plasma at 25 mg/kg, po by HPLC analysis2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Towards a modern definition of vitamin E-evidence for a quinone hypothesis.
AID642431Cmax in rat plasma at 100 mg/kg, po by HPLC analysis2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Towards a modern definition of vitamin E-evidence for a quinone hypothesis.
AID642434Tmax in rat plasma at 100 mg/kg, po by HPLC analysis2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Towards a modern definition of vitamin E-evidence for a quinone hypothesis.
AID641759Ratio of CoQ10 EC50 to compound EC50 for cytoprotection against BSO-induced human FRDA primary patient fibroblasts2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Towards a modern definition of vitamin E-evidence for a quinone hypothesis.
AID1233172Antimicrobial activity against Staphylococcus aureus after 5 to 12 hrs by micro broth dilution assay2015Bioorganic & medicinal chemistry letters, Jul-01, Volume: 25, Issue:13
Synthesis and bioactivity of tripolinolate A from Tripolium vulgare and its analogs.
AID642428Growth inhibition of human primary fibroblasts after 48 hrs by calcein-AM-based cell viability assay2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Towards a modern definition of vitamin E-evidence for a quinone hypothesis.
AID641744Clearance in mouse plasma at 5 mg/kg, iv by HPLC analysis2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Towards a modern definition of vitamin E-evidence for a quinone hypothesis.
AID502770Cytotoxicity against human SF268 cells after 72 hrs by MTS reduction assay2010Journal of natural products, Sep-24, Volume: 73, Issue:9
Cytotoxic flavonoids from the leaves of Cryptocarya chinensis.
AID641737AUC (0 to infinity) in rat plasma at 100 mg/kg, po by HPLC analysis2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Towards a modern definition of vitamin E-evidence for a quinone hypothesis.
AID1176106Inhibition of SHP2 (unknown origin) using pNPP as substrate at 20 ug/ml by spectrophotometry2015Bioorganic & medicinal chemistry, Jan-01, Volume: 23, Issue:1
Bioactive constituents from the green alga Caulerpa racemosa.
AID642433Tmax in mouse plasma at 10 mg/kg, po by HPLC analysis2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Towards a modern definition of vitamin E-evidence for a quinone hypothesis.
AID641752Inhibition of CYP1A2 at 10 uM2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Towards a modern definition of vitamin E-evidence for a quinone hypothesis.
AID642430Cmax in mouse plasma at 10 mg/kg, po by HPLC analysis2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Towards a modern definition of vitamin E-evidence for a quinone hypothesis.
AID641749Inhibition of CYP2C9 at 10 uM2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Towards a modern definition of vitamin E-evidence for a quinone hypothesis.
AID641741Half life in rat plasma at 100 mg/kg, po by HPLC analysis2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Towards a modern definition of vitamin E-evidence for a quinone hypothesis.
AID642436AUCt in mouse plasma at 5 mg/kg, iv by HPLC analysis2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Towards a modern definition of vitamin E-evidence for a quinone hypothesis.
AID642437AUCt in mouse plasma at 10 mg/kg, po by HPLC analysis2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Towards a modern definition of vitamin E-evidence for a quinone hypothesis.
AID641755Toxicity in Wistar rat assessed as changes in food intake up to 2000 mg/kg, qd for 14 days2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Towards a modern definition of vitamin E-evidence for a quinone hypothesis.
AID641761Ratio of alpha-tocopherol EC50 to compound EC50 for cytoprotection against BSO-induced human FRDA primary patient fibroblasts2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Towards a modern definition of vitamin E-evidence for a quinone hypothesis.
AID642426Cytoprotective activity against BSO-induced human FRDA primary patient fibroblasts compound pretreated 12 hrs prior to BSO-induction measured after 48 hrs by calcein-AM-based cell viability assay2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Towards a modern definition of vitamin E-evidence for a quinone hypothesis.
AID1176097Inhibition of purified recombinant PTP1B catalytic domain (unknown origin) using pNPP as substrate by spectrophotometry2015Bioorganic & medicinal chemistry, Jan-01, Volume: 23, Issue:1
Bioactive constituents from the green alga Caulerpa racemosa.
AID1176107Inhibition of LAR (unknown origin) using pNPP as substrate at 20 ug/ml by spectrophotometry2015Bioorganic & medicinal chemistry, Jan-01, Volume: 23, Issue:1
Bioactive constituents from the green alga Caulerpa racemosa.
AID641758Prolongation of partial thromboplastin time in female Wistar rat2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Towards a modern definition of vitamin E-evidence for a quinone hypothesis.
AID502769Cytotoxicity against human NCI-H460 cells after 72 hrs by MTS reduction assay2010Journal of natural products, Sep-24, Volume: 73, Issue:9
Cytotoxic flavonoids from the leaves of Cryptocarya chinensis.
AID641738AUC (0 to infinity) in dog plasma at 25 mg/kg, po by HPLC analysis2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Towards a modern definition of vitamin E-evidence for a quinone hypothesis.
AID642432Cmax in dog plasma at 25 mg/kg, po by HPLC analysis2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Towards a modern definition of vitamin E-evidence for a quinone hypothesis.
AID1176110Cytotoxicity against human A549 cells by SRB assay2015Bioorganic & medicinal chemistry, Jan-01, Volume: 23, Issue:1
Bioactive constituents from the green alga Caulerpa racemosa.
AID502768Cytotoxicity against human MCF7 cells after 72 hrs by MTS reduction assay2010Journal of natural products, Sep-24, Volume: 73, Issue:9
Cytotoxic flavonoids from the leaves of Cryptocarya chinensis.
AID1176109Cytotoxicity against human HL60 cells by SRB assay2015Bioorganic & medicinal chemistry, Jan-01, Volume: 23, Issue:1
Bioactive constituents from the green alga Caulerpa racemosa.
AID642435Tmax in dog plasma at 25 mg/kg, po by HPLC analysis2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Towards a modern definition of vitamin E-evidence for a quinone hypothesis.
AID641739Half life in mouse plasma at 5 mg/kg, iv by HPLC analysis2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Towards a modern definition of vitamin E-evidence for a quinone hypothesis.
AID713897Antimycobacterial activity against Mycobacterium tuberculosis H37Rv2012European journal of medicinal chemistry, Mar, Volume: 49Recent advances in antitubercular natural products.
AID1176099Inhibition of CDC25B (unknown origin) using pNPP as substrate by spectrophotometry2015Bioorganic & medicinal chemistry, Jan-01, Volume: 23, Issue:1
Bioactive constituents from the green alga Caulerpa racemosa.
AID641746Mutagenic activity in Salmonella Typhimurium by Ames test2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Towards a modern definition of vitamin E-evidence for a quinone hypothesis.
AID641736AUC (0 to infinity) in mouse plasma at 10 mg/kg, po by HPLC analysis2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Towards a modern definition of vitamin E-evidence for a quinone hypothesis.
AID641751Inhibition of CYP2D6 at 10 uM2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Towards a modern definition of vitamin E-evidence for a quinone hypothesis.
AID641747Induction of micronucleation in CHO cells2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Towards a modern definition of vitamin E-evidence for a quinone hypothesis.
AID641756Toxicity in Wistar rat assessed as changes in water intake up to 2000 mg/kg, qd for 14 days2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Towards a modern definition of vitamin E-evidence for a quinone hypothesis.
AID641760Ratio of idebenone EC50 to compound EC50 for cytoprotection against BSO-induced human FRDA primary patient fibroblasts2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Towards a modern definition of vitamin E-evidence for a quinone hypothesis.
AID641740Half life in mouse plasma at 10 mg/kg, po by HPLC analysis2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Towards a modern definition of vitamin E-evidence for a quinone hypothesis.
AID641753Solubility of the compound2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Towards a modern definition of vitamin E-evidence for a quinone hypothesis.
AID641734AUCt in dog plasma at 25 mg/kg, po by HPLC analysis2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Towards a modern definition of vitamin E-evidence for a quinone hypothesis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (135)

TimeframeStudies, This Drug (%)All Drugs %
pre-199045 (33.33)18.7374
1990's31 (22.96)18.2507
2000's35 (25.93)29.6817
2010's19 (14.07)24.3611
2020's5 (3.70)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.41 (24.57)
Research Supply Index5.01 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.41)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (2.05%)5.53%
Reviews8 (5.48%)6.00%
Case Studies0 (0.00%)4.05%
Observational1 (0.68%)0.25%
Other134 (91.78%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 2a, Double Blind, Randomized, Placebo-controlled, 28 Day, Two-arm, Parallel Group Study of A0001 in Patients With the A3243G Mitochondrial DNA Point Mutation and Evidence of Impaired Mitochondrial Function [NCT01074359]Phase 230 participants (Anticipated)Interventional2010-02-28Terminated(stopped due to Terminated for Commercial Reasons. There were no safety issues involved in the decision to terminate the study.)
A Phase 2a, Double-Blind, Randomized, Placebo-Controlled, 28 Day, Three-arm, Parallel Group Study of A0001 in the Treatment of Subjects With Friedreich's Ataxia [NCT01035671]Phase 242 participants (Anticipated)Interventional2009-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]